<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04248283</url>
  </required_header>
  <id_info>
    <org_study_id>UM08</org_study_id>
    <nct_id>NCT04248283</nct_id>
  </id_info>
  <brief_title>Adjustable Continence Therapy (ACT) for the Treatment of Female SUI</brief_title>
  <official_title>A Clinical Investigation of the Adjustable Continence Therapy (ACT) for Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uromedica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uromedica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The&#xD;
      purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable&#xD;
      Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary&#xD;
      incontinence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A prospective, single arm, non-randomized, multicenter, prospective case-series trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Provocative pad weight</measure>
    <time_frame>12 months</time_frame>
    <description>Change in provocative pad weight from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urogenital Distress Inventory (UDI)</measure>
    <time_frame>12 months</time_frame>
    <description>Six item questionnaire. Scores range from 0-100. 0 being not distressed, 100 being very distressed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence Quality of Life Questionnaire (I-QOL)</measure>
    <time_frame>12 months</time_frame>
    <description>Twenty-two item questionnaire. Scores range from 0-100. 0 being lowest quality of life, 100 being highest quality of life.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Complete adverse event profile</measure>
    <time_frame>12 months</time_frame>
    <description>Collection of patient safety information</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">167</enrollment>
  <condition>Urinary Incontinence</condition>
  <condition>Urinary Incontinence,Stress</condition>
  <arm_group>
    <arm_group_label>Adjustable Continence Therapy for Women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of the Adjustable Continence Therapy for the treatment of female SUI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Adjustable Continence Therapy for Women (ACT)</intervention_name>
    <description>Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately).</description>
    <arm_group_label>Adjustable Continence Therapy for Women</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female at least 22 years old&#xD;
&#xD;
          2. Diagnosed with stress urinary incontinence with primary Intrinsic Sphincter Deficiency&#xD;
&#xD;
          3. Provocative pad weight of greater than 11.0 grams&#xD;
&#xD;
          4. Candidate for surgical intervention&#xD;
&#xD;
          5. Negative urinalysis&#xD;
&#xD;
          6. Normal cystourethroscopy&#xD;
&#xD;
          7. Failed at least 6 months of previous treatment(s) for stress urinary incontinence&#xD;
             (e.g., exercise regimen, electrical stimulation, surgical procedures, etc). Note:&#xD;
             patients may have failed prior anti-incontinence procedures for SUI (e.g., suspension,&#xD;
             sling, or urethral bulking agent)&#xD;
&#xD;
          8. Willing and able to sign informed consent and comply with trial follow-up requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating&#xD;
&#xD;
          2. Life expectancy of less than 5 years&#xD;
&#xD;
          3. Has uncontrolled diabetes as evidenced by HbA1c over 6.5% and fasting plasma glucose&#xD;
             over 130 mg/dL&#xD;
&#xD;
          4. Has auto-immune disease&#xD;
&#xD;
          5. Undergoing radiation therapy&#xD;
&#xD;
          6. Active urinary tract infection&#xD;
&#xD;
          7. Detrusor instability refractory to medication&#xD;
&#xD;
          8. Reduced bladder compliance as defined by a cystometrogram&#xD;
&#xD;
          9. Significant residual volume (greater than 100 ml) after voiding in which detrusor&#xD;
             contraction is weak, when the bladder volume is greater than or equal to 250 ml&#xD;
&#xD;
         10. Has, had, or is suspected of having bladder cancer&#xD;
&#xD;
         11. History of bladder stones&#xD;
&#xD;
         12. Urethral stricture evidenced during cystourethroscopy&#xD;
&#xD;
         13. Has a neurogenic bladder that is atonic or has detrusor sphincter dyssynergia&#xD;
&#xD;
         14. Has a diathesis, hemophilia, or a bleeding disorder&#xD;
&#xD;
         15. Has a rectocele, cystocele, urethrocele, enterocele, or pelvic prolapse of grade 3 or&#xD;
             higher&#xD;
&#xD;
         16. Had prior pelvic radiotherapy&#xD;
&#xD;
         17. Had a prior artificial urinary sphincter implanted&#xD;
&#xD;
         18. Has a neurogenic condition known to affect bladder/sphincter function&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy C Cook, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Uromedica, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Project Manager</last_name>
    <phone>763-999-7048</phone>
    <email>tplouffe@uromedica-inc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHI Health Research Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Granados</last_name>
      <email>crystal.granados@alegent.org</email>
    </contact>
    <investigator>
      <last_name>Michael Feloney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virtua Health, Inc.</name>
      <address>
        <city>Moorestown</city>
        <state>New Jersey</state>
        <zip>08057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharine Ference</last_name>
      <phone>856-761-3903</phone>
      <email>kference@virtua.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Maccarone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>C. Sage Claydon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Jenkins</last_name>
      <email>jenkijn@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Rovner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reba Blissell</last_name>
      <phone>206-616-8723</phone>
      <email>blissr@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Suzette Sutherland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Incontinence</keyword>
  <keyword>Urination Disorders</keyword>
  <keyword>Urination Involuntary</keyword>
  <keyword>Urologic Diseases</keyword>
  <keyword>Lower Urinary Tract Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

